The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...

The vaccine acts like a "wanted poster" unmasking cancer cells that are adept at hiding in the body, only to resurface later.

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver mutations and induce antitumor immunity, ...